The INFINITY clinical trial revealed that Imeglimin therapy can prolong red blood cell lifespan, artificially lowering HbA1c readings. Researchers emphasize re-evaluating glycemic monitoring strategies for patients on this drug to ensure accurate metabolic assessment and treatment adjustment. To read more click here ##Reference## Osonoi T, Shirabe S, Saito M, et al. Imeglimin may affect hemoglobin A1c accuracy via erythrocyte lifespan prolongation: insights from the INFINITY trial.
Front Endocrinol. 2025;13:1699591.## What key HbA1c limitation does Imeglimin introduce? a) RBC lifespan prolongation b) Increased renal clearance c) Enhanced insulin degradation d) Reduced plasma glucose sensitivity
